Vote Scores

Home / Companies / Krystal Biotech, Inc.

Company · votes reported on Form N-PXKRYS · SEC company no. 1711279

Krystal Biotech, Inc.

How funds and institutional managers reported voting their shares, year to 30 June 2026

Filers reporting
502year to 30 June 2026
Against management on pay
7.2%34 of 473 reporting filers
Same, by reported shares
5.8%shares reported on Form N-PX
Meetings on file
3across 3 seasons
87.0% for7.0% against6.0% other7.2% against management500 filers on say-on-pay

foragainstabstain, withhold or otheramber tick: the portion cast against management

For the year to 30 June 2026, 502 funds and managers listed Krystal Biotech, Inc. in their Form N-PX filings (one meeting).

On the advisory vote on executive pay, 34 of the 473 filers that reported a position voted against management (7.2%), close to the median company on this site (6.6%). By reported shares the figure is 5.8% (median 2.9%). These are shares of the filers reporting on Form N-PX, not of all votes cast at the meeting.

Among the largest fund families, 47 voted with management on pay and 2 voted against: American Century and Capital Group and American Funds.

Meetings

Meeting dateSeasonFilers reportingItemsAgainst management on pay
15 May 2026year to 30 June 202650247.2%
16 May 2025year to 30 June 2025443311.3%
17 May 2024year to 30 June 202436237.8%

Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.

Say-on-pay: this company and the median

year to 30 June 2026Krystal Biotech, Inc.Median company
Reporting filers voting against management7.2%6.6%
Reported shares voted against management5.8%2.9%

Among filers reporting on Form N-PX. The median is over 3,799 companies with a say-on-pay item reported by 20 or more filers.

How the largest families voted

Meeting of 15 May 2026: say-on-pay and each shareholder proposal that could be told apart.

FamilySay-on-pay
VanguardFor
BlackRock and iSharesFor
FidelityFor
DimensionalFor
State Street and SPDRFor
American CenturyAgainst *
Franklin TempletonFor
InvescoFor
EquitableFor
Charles SchwabFor
Nuveen and TIAAFor
ProShares and ProFundsFor
John Hancock and ManulifeFor
Morgan Stanley, Eaton Vance and CalvertFor
J.P. MorganFor
Goldman SachsFor
WisdomTreeFor
PGIM and PrudentialFor
Jackson National fundsFor
Northern Trust and FlexSharesFor
SEIFor
T. Rowe PriceFor
ThriventFor
Lincoln FinancialFor
VoyaFor
First TrustFor
Russell InvestmentsFor
NationwideFor
Victory CapitalFor
Brighthouse FundsFor
Guggenheim and RydexFor
Columbia ThreadneedleFor
BNY MellonFor
PrincipalFor
Capital Group and American FundsAgainst *
Pacific Life fundsFor
Global XFor
TransamericaFor
Federated HermesFor
AllianceBernsteinFor
DWSFor
AllspringFor
MassMutualFor
VirtusFor
Janus HendersonFor
Neuberger BermanFor
Natixis and Loomis SaylesFor
Lord AbbettFor
BairdFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

By season

SeasonFilers reportingAgainst management on pay, filersBy reported sharesSay-on-pay split
year to 30 June 20243627.8%4.0%
year to 30 June 202544511.3%7.8%
year to 30 June 20265027.2%5.8%

Category mix

Share of the vote records reported for this company, by the category filers chose.

CategoryVote recordsShare
DIRECTOR ELECTIONS2,63243.6%
SECTION 14A SAY-ON-PAY VOTES2,03933.8%
AUDIT-RELATED1,00216.6%
COMPENSATION3585.9%

Questions

How did large funds vote at Krystal Biotech, Inc.?

For the year to 30 June 2026, 473 Form N-PX filers reported a say-on-pay vote at Krystal Biotech, Inc.; 34 voted against management (7.2%). The table on this page lists the position of each of the largest fund families on say-on-pay and on each shareholder proposal that could be told apart in the filings.

Were there shareholder proposals at Krystal Biotech, Inc.?

No proposal from security holders was reported by enough filers to be shown for the year to 30 June 2026.

Is this the meeting result?

No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which Krystal Biotech, Inc. reports on Form 8-K.

Where does the data come from?

From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 23 Sep 2026; the median compares 3,799 companies.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Krystal Biotech, Inc., grouped by company. The name is the most common spelling among filers; the ticker and SEC company number come from the SEC company tickers file, matched on the exact name. Not verified by the SEC. Filings read through 23 Sep 2026; page built 26 Sep 2026.